Anvisa - Brazilian Health Regulatory Agency (2022) Notification of Temporary Discontinuation: Alglucosidase alfa. Available at: https://sad.anvisa.gov.br/MicroStrategy/servlet/mstrWeb. Accessed 18 Dec 2024

Anvisa - Brazilian Health Regulatory Agency (2023) Notification of Temporary Discontinuation: Avalglucosidase alfa. Available at: https://sad.anvisa.gov.br/MicroStrategy/servlet/mstrWeb. Accessed 18 Dec 2024

Anvisa - Brazilian Health Regulatory Agency (2021) Sanitary register: Avalglucosidase alfa. Available at: https://consultas.anvisa.gov.br/#/medicamentos/2034225?substancia=32068. Accessed 18 Dec 2024

Anvisa - Brazilian Health Regulatory Agency, & Drug Market Regulation Chamber (2024) Lists of drug prices. Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/precos. Accessed 18 Dec 2024

Anvisa - Brazilian Health Regulatory Agency (2007) Sanitary register: Alglucosidase alfa. Available at: https://consultas.anvisa.gov.br/#/medicamentos/1323181?substancia=25925. Accessed 18 Dec 2024

Anvisa - Brazilian Health Regulatory Agency (2017) Resolution of the Collegiate Board 205, of December 28, 2017. Available at: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2017/rdc0205_28_12_2017.pdf. Accessed 18 Dec 2024

Brazil (1990) Law No. 8.080, of September 19, 1990. Available at: https://www.planalto.gov.br/ccivil_03/leis/l8080.htm. Accessed 18 Dec 2024

Brazil (2010) From exceptionality to care lines: the Specialized Component of Pharmaceutical Assistance. Accessed 18 Dec 2024

Brazil (2014) Ordinance No. 199, of January 30, 2014. Available at: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2014/prt0199_30_01_2014.html. Accessed 18 Dec 2024

Brazil (2019) Alglucosidase alfa as enzyme replacement therapy for Pompe disease. Available at: https://www.gov.br/conitec/pt-br/midias/relatorios/2019/relatorio_alfaalglicosidase_pompe.pdf. Accessed 18 Dec 2024

Brazil (2020) Clinical Protocol and Therapeutic Guidelines for Pompe Disease. Available at: http://antigo-conitec.saude.gov.br/images/Relatorios/2020/Relatorio_de_Recomendacao_PCDT_Doenca_de_pompe_FINAL_529_2020.pdf. Accessed 18 Dec 2024

Brazil (2021) Alglucosidase alfa as enzyme replacement therapy for late-onset Pompe disease. Available at: https://www.gov.br/conitec/pt-br/midias/relatorios/2021/20210602_relatorio_617_alfa-alglicosidase_dpit_p24.pdf. Accessed 18 Dec 2024

Brazil (2023) Ordinance GM/MS No. 2.261, of December 8, 2023. Available at: https://www.in.gov.br/web/dou/-/portaria-gm/ms-n-2.261-de-8-de-dezembro-de-2023-529259361. Accessed 18 Dec 2024

Brazil (2022d) Ordinance GM/MS No. 4.228, of December 6, 2022. Available at: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2022/prt4228_07_12_2022.html. Accessed 18 Dec 2024

Brazil (2024a) Contracts of the Department of Health Logistics - DLOG. Available at: https://www.gov.br/saude/pt-br/acesso-a-informacao/licitacoes-e-contratos/contratos-dlog. Accessed 18 Dec 2024

Brazil (2024b) Requests for Health Technology Assessment. Available at: https://www.gov.br/conitec/pt-br/assuntos/avaliacao-de-tecnologias-em-saude/tecnologias-demandadas. Accessed 18 Dec 2024

Brazil (2024c) Topic 1234 - Passive legitimacy of the Union and competence of the Federal Court in lawsuits concerning the supply of drugs registered with the National Health Surveillance Agency - ANVISA, but not standardized in the Unified Health System - SUS. Available at: https://portal.stf.jus.br/jurisprudenciaRepercussao/tema.asp?num=1234. Accessed 18 Dec 2024

Brazil (2022f) Extrajudicial report: DMPF-e No. 18/2022. Available at: http://www.transparencia.mpf.mp.br/conteudo/diarios-e-boletins/diario-eletronico-dmpf-e/2022/DMPF-EXTRAJUDICIAL-2022-01-27.pdf. Accessed 18 Dec 2024

Brazil (2022c) National List of Essential Medicines (RENAME) 2022. https://www.conass.org.br/wp-content/uploads/2022/01/RENAME-2022.pdf. Available at: Accessed 18 Dec 2024

Brazil (2022e) Onasemnogene abeparvovec for the treatment of spinal muscular atrophy (SMA). Available at: https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2022/20221207_relatorio_zolgensma_ame_tipo_i_793_2022.pdf. Accessed 18 Dec 2024

Brazil (2022a) The use of cost-effectiveness thresholds in health decisions: Recommendations from the National Commission for the Incorporation of Technologies in SUS. Available at: https://www.gov.br/conitec/pt-br/midias/pdf/2022/20221106_relatorio-uso-de-limiares-de-custo-efetividade-nas-decisoes-em-saude.pdf. Accessed 18 Dec 2024

Brazil (2022b) Alglucosidase alfa (Myozyme®) for the treatment of late-onset Pompe disease. Available at: https://www.gov.br/conitec/pt-br/midias/relatorios/2022/20220927_relatorio_769_alfaalglicosidase_final.pdf. Accessed 18 Dec 2024

CADTH - Canadian Agency for Drugs and Technologies in Health (2024b) Available at: https://www.cadth.ca/avalglucosidase-alfa. Accessed 18 Dec 2024

CADTH - Canadian Agency for Drugs and Technologies in Health (2024a) Alglucosidase. Available at: https://www.cadth.ca/alglucosidase. Accessed 18 Dec 2024

Chile, Ministry of Health (2017) Enfermedad de Pompe. Available at: https://docs.bvsalud.org/biblioref/2018/04/882714/enfermedad-de-pompe-ok.pdf. Accessed 18 Dec 2024

Chile, Ministry of Health (2018) Enfermedad de Pompe. Available at: https://docs.bvsalud.org/biblioref/2019/10/1021880/enfermedad_pompe.pdf. Accessed 18 Dec 2024

Côté A, Keating B (2012) What is wrong with orphan drug policies? Value Health 15(8):1185–1191. https://doi.org/10.1016/j.jval.2012.09.004

Article  PubMed  Google Scholar 

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT (2012) Consensus treatment recommendations for late-onset pompe disease. Muscle Nerve 45(3):319–333. https://doi.org/10.1002/mus.22329

Article  PubMed  Google Scholar 

Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Zagnoli F (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20(12):1012–1026. https://doi.org/10.1016/S1474-4422(21)00241-6

Article  PubMed  CAS  Google Scholar 

Dornelles AD, Junges APP, Pereira TV, Krug BC, Gonçalves CBT, Llerena JC, Kishnani PS, de Oliveira HA, Schwartz IVD (2021) A systematic review and meta-analysis of enzyme replacement therapy in late-onset pompe disease. J Clin Med 10(21):4828. https://doi.org/10.3390/jcm10214828

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dornelles AD, Junges APP, Krug B, Gonçalves C, de Oliveira Junior HA, Schwartz IVD (2024) Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset pompe disease: a systematic review and meta-analysis. Front Pediatr 12. https://doi.org/10.3389/fped.2024.1310317

EMA - European Medicines Agency (2024b) Nexviadyme. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme. Accessed 18 Dec 2024

EMA - European Medicines Agency (2024a) Myozyme. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/myozyme#assessment-history. Accessed 18 Dec 2024

FDA - Food and Drug Administration (2013) Orphan Drug Act - Relevant Excerpts. Available at: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts. Accessed 18 Dec 2024

FDA - Food and Drug Administration (2024a) Drug approval package: Myozyme (alglucosidase alfa). Available ate: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125141s000_MyozymeTOC.cfm. Accessed 18 Dec 2024

FDA - Food and Drug Administration (2024b) Drug approval package: Nexviazyme (avalglucosidase alfa). Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nexviazyme. Accessed 18 Dec 2024

Gammie T, Lu CY, Babar ZU-D (2015) Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE 10(10):e0140002. https://doi.org/10.1371/journal.pone.0140002

Article  PubMed  PubMed Central  CAS  Google Scholar 

HAS - Haute Autorité de Santé (2024a) Myozyme (alpha-alglucosidase). Available at: https://www.has-sante.fr/jcms/pprd_2983670/en/myozyme-alpha-alglucosidase. Accessed 18 Dec 2024

HAS - Haute Autorité de Santé (2024b) Nexviadyme (avalglucosidase alfa). Available at: https://www.has-sante.fr/jcms/p_3374119/en/nexviadyme-avalglucosidase-alfa. Accessed 18 Dec 2024

HAS - Haute Autorité de Santé (2024c) Pombiliti (cipaglucosidase alfa). Available at: https://www.has-sante.fr/jcms/p_3456871/en/pombiliti-cipaglucosidase-alfa. Accessed 18 Dec 2024

Hasan SS, Lu CY, Babar ZU-D (2018) Access to high-cost medicines: an overview. Equitable Access to high-cost pharmaceuticals. Elsevier, pp 1–10. https://doi.org/10.1016/B978-0-12-811945-7.00001-4

IETSI - Instituto de Evaluación de Tecnologías en Salud e Investigación (2019a) Dictamen N° 040-SDEPFyOTS-DETS-IETSI-2019. Available at: https://ietsi.essalud.gob.pe/dictamenes/dictamen-n-040-sdepfyots-dets-ietsi-2019/. Accessed 18 Dec 2024

IETSI - Instituto de Evaluación de Tecnologías en Salud e Investigación (2019b) Dictamen N° 019-SDEPFyOTS-DETS-IETSI-2019. Available at: https://ietsi.essalud.gob.pe/dictamenes/dictamen-n-019-sdepfyots-dets-ietsi-2019/. Accessed 18 Dec 2024

Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O’Grady G, Patterson MC, Rapoport DM, Slonim A, Watson MS (2006) Pompe disease diagnosis and management guideline. Genet Med 8(5):267–288. https://doi.org/10.1097/01.gim.0000218152.87434.f3

Article  PubMed  PubMed Central  Google Scholar 

Klemp M, Frønsdal KB, Facey K (2011) What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 27(1):77–83. https://doi.org/10.1017/S0266462310001297

Article  PubMed  Google Scholar 

Llerena Junior JC, Nascimento OJM, Oliveira ASB, Dourado Junior MET, Marrone CD, Siqueira HH, Sobreira CFR, Dias-Tosta E, Werneck LC (2015) Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult pompe disease. Arq Neuropsiquiatr 74(2):166–176. https://doi.org/10.1590/0004-282X20150194

Article  PubMed  Google Scholar 

National Institute of Industrial Property (2024) Patent: BR 11 2014 022624 5 A2. Available at: https://busca.inpi.gov.br/PePI/. Accessed 18 Dec 2024

NHS England (2024) Cancer drugs fund. Available at: https://www.england.nhs.uk/cancer/cdf/. Accessed 18 Dec 2024

NICE - National Institute for Health and Care Excellence (2023) Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. Available at: https://www.nice.org.uk/guidance/ta912. Accessed 18 Dec 2024

NICE - National Institute for Health and Care Excellence (2022) Avalglucosidase alfa for treating Pompe disease. Available at: https://www.nice.org.uk/guidance/ta821. Accessed 18 Dec 2024

OECD - Organisation for Economic Co-operation and Development (2024) Performance-based managed entry agreements for new medicines. Available at: https://web-archive.oecd.org/temp/2023-04-20/539425-pharma-managed-entry-agreements.htm. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2011) Alglucosidase - Public Summary Document, July 2011. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-07/pbac-psd-alglucosidase-july11. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2013) Alglucosidase - Public Summary Document, March 2013. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-03/alglucosidase. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2012) Alglucosidase alfa - Public Summary Document, November 2012. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/alglucosidase-alfa-rch. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2010) Alglucosidase alfa - Public Summary Document, November 2010. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2010-11/pbac-psd-alglucosidase-alfa-nov10. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2009) Alglucosidase - Public Summary Document, November 2009. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2009-11/pbac-psd-Alglucosidase-nov09. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2008) Alglucosidase - Public Summary Document, July 2008. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-07/pbac-psd-alglucosidase-july08. Accessed 18 Dec 2024

PBAC - Pharmaceutical Benefits Advisory Committee (2021) Recommendations made by the PBAC, November 2021. Available at: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-november-2021. Accessed 18 Dec 2024

Sanofi (2023) Comunicado sobre a descontinuação temporária de fabricação/importação do medicamento LASIX® (furosemida) 10 mg/mL solução injetável. Available at: https://www.sanofi.com.br/pt/noticias/informacoes-de-produtos/2023-04-18-descontinuacao-nexviazyme. Accessed 18 Dec 2024

Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS, Sebok A, Pestronk A, Dominovic-Kovacevic A, Khan A, Chien YH (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20(12):1027–1037. https://doi.org/10.1016/S1474-4422(21)00331-8

Article  PubMed  CAS  Google Scholar 

SMC - Scottish Medicines Consortium (2007) Alglucosidase alfa (Myozyme®). Available at: https://scottishmedicines.org.uk/medicines-advice/alglucosidase-alfa-myozyme-fullsubmission-35207/. Accessed 18 Dec 2024

SMC - Scottish Medicines Consortium (2023a) Avalglucosidase alfa (Nexviadyme). Available at: https://scottishmedicines.org.uk/medicines-advice/avalglucosidase-alfa-nexviadyme-abb-smc2546/. Accessed 18 Dec 2024

SMC - Scottish Medicines Consortium (2023b) Cipaglucosidase alfa (Pombiliti). Available at: https://scottishmedicines.org.uk/medicines-advice/cipaglucosidase-alfa-pombiliti-abb-smc2606/. Accessed 18 Dec 2024

Souza MV, Krug BC, Picon PD, Schwartz IVD (2010) Medicamentos De alto custo para doenças raras no Brasil: o exemplo das doenças lisossômicas. Cien Saude Colet 15(Suppl 3):3443–3454. https://doi.org/10.1590/S1413-81232010000900019

Article  PubMed  Google Scholar 

Trotta F, Guerrizio MA, Di Filippo A, Cangini A (2023) Financial outcomes of managed entry agreements for pharmaceuticals in Italy. JAMA Health Forum 4(12):e234611. https://doi.org/10.1001/jamahealthforum.2023.4611

Article  PubMed  PubMed Central  Google Scholar 

van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372(9646):1342–1353. https://doi.org/10.1016/S0140-6736(08)61555-X

Article